Sorrento Presents Preliminary Results of STI-2020 Against COVID-19
Shots: AJOVY (remanezumab-vfrm) is evaluated in two P-III trial enrolling patients with disabling migraine, administering AJOVY alone and in combination with oral preventive treatments, showing reduction in monthly migraine days in 12 wks. duration having injection site reactions as adverse effects The US Wholesale Acquisition Cost (WAC) of AJOVY for monthly and the quarterly dose […]Read More
